| Name | Title | Contact Details |
|---|
BLOSSOM SOUTH is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rhapsody partners with healthcare organizations around the globe delivering its adaptable Interoperability Suite to reliably connect, classify, and clean data. Rhapsody health solutions power the applications and workflows that improve clinical, operational, and financial outcomes today while helping teams respond to and prepare for changes on the horizon. Rhapsody is committed to empowering people throughout the healthcare ecosystem, from specialty clinics to large care networks, from public health to health technology, and everything in between.
Modern Health is the comprehensive mental health and wellness platform that combines the WHO well-being assessment, self-service wellness kits, a global network of certified coaches, and licensed therapists available in 35 languages all available in a single app. Modern Health empowers employers to lead the charge in acknowledging that mental health is just as important as physical health, destigmatizing the conversation, and increasing accessibility of mental health services for all. Founded in 2017, Modern Health incorporates evidence-based psychology principles and seamless technology to serve the needs of companies globally. Headquartered in San Francisco, Modern Health has raised more than $172 million from Founders Fund, Battery Ventures, Felicis Ventures, Kleiner Perkins, Afore Capital, MGV, Frederic Kerrest (co-founder of Okta), and 01 Advisors.
The Indiana Hemophilia & Thrombosis Center (IHTC) is the only federally recognized comprehensive hemophilia treatment center in Indiana and one of the largest centers in the nation. The IHTC is a 501(c)3 nonprofit entity that is dedicated to providing the best, most comprehensive care to people in Indiana with bleeding or clotting disorders and to their families. The IHTC is both nationally and internationally distinguished as a Center of Excellence for its leadership in bleeding disorder patient care, education and research.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.